MedTrace Logo

Impact of TTC Following Neoadjuvant Chemotherapy on the Prognosis of LAGC

NCT06696963 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 524

Last updated 2024-11-20

No results posted yet for this study

Summary

he present study retrospectively analyzed the clinicopathological data of 524 patients diagnosed with LAGC who underwent D2 radical gastrectomy after NACT between January 2010 and December 2021 at 2 centers. This study was conducted in accordance with the ethical principles outlined in the World Medical Association's Declaration of Helsinki. Informed consent was obtained from all patients and their legal guardians. All procedures were approved by the institutional review board.

Conditions

Sponsors & Collaborators

  • Fujian Medical University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
84 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-15
Primary Completion
2024-04-15
Completion
2024-04-17

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06696963 on ClinicalTrials.gov